NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing

Core Viewpoint - NervGen Pharma Corp. is set to ring the closing bell at the Nasdaq Stock Market on January 22, 2026, marking a significant milestone in the company's growth and evolution as a clinical-stage biopharmaceutical company focused on neuroreparative therapeutics for spinal cord injury and other neurological conditions [1][3]. Company Overview - NervGen Pharma Corp. is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics aimed at transforming the lives of individuals with spinal cord injury (SCI) by enabling the nervous system to repair itself [4]. - The company's lead therapeutic candidate, NVG-291, is a subcutaneously administered neuroreparative peptide that has shown durable improvement in function, independence, and quality of life in individuals with chronic SCI [4]. - NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency (EMA) for the treatment of SCI, with ongoing enrollment in a Phase 1b/2a clinical study and preparations for a Phase 3 trial [4]. Leadership and Recognition - Adam Rogers, MD, Chairman and Interim Chief Executive Officer, emphasized the honor of participating in the Nasdaq closing bell ceremony and acknowledged the support from shareholders, collaborators, and families involved in clinical research [3]. - The event will be livestreamed from the Nasdaq MarketSite Tower, showcasing the company's mission and achievements to a broader audience [3].